- Trials with a EudraCT protocol (237)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
237 result(s) found for: HIV drug resistance.
Displaying page 1 of 12.
EudraCT Number: 2009-015647-16 | Sponsor Protocol Number: ANV-09-008 | Start Date*: 2010-01-28 | |||||||||||
Sponsor Name:GUIDE Clinic, St James's Hospital | |||||||||||||
Full Title: The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users. | |||||||||||||
Medical condition: HIV-1 Positive Injection Drug Users | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001058-26 | Sponsor Protocol Number: P04285 | Start Date*: 2006-01-09 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: Vicriviroc (SCH 417690) in Combination Treatment with Optimized ART Regimen in Experienced Subjects (VICTOR-E2) | |||||||||||||
Medical condition: HIV infection (mixed X4/R5 torpism) with previous therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003881-32 | Sponsor Protocol Number: 023-01 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:Merck & Co, Inc | |||||||||||||
Full Title: Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options. | |||||||||||||
Medical condition: HIV-1 infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) SE (Prematurely Ended) AT (Completed) NL (Completed) LV (Completed) IT (Completed) EE (Completed) SI (Completed) IE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002460-98 | Sponsor Protocol Number: VS411-C201 | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:VIROSTATICS, SRL | |||||||||||||
Full Title: A randomized double-blind dose-finding multi-centre phase IIa study with VS411 for HIV-1 infection. | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002978-35 | Sponsor Protocol Number: HLS05/2008 | Start Date*: 2008-07-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants | |||||||||||||
Medical condition: First line therapy of HIV-1-infected patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005951-40 | Sponsor Protocol Number: ITHACA | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:Fundació Lluita contra la Sida | |||||||||||||
Full Title: DINAMICA VIRAL DEL VIH-1 EN SUJETOS QUE INICIAN TERAPIA CON RALTEGRAVIR (HIV-1 VIRAL DYNAMICS IN SUBJECTS INITIATING RALTEGRAVIR THERAPY) | |||||||||||||
Medical condition: Pacientes con infección VIH-1 (HIV-1 infection) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002319-13 | Sponsor Protocol Number: EfaRiLipidomics | Start Date*: 2015-08-28 | |||||||||||
Sponsor Name:Fundació Hospital Vall Hebron Institut de Recerca | |||||||||||||
Full Title: Outcome of plasma lipid profile in patients switching from Atripla® to Eviplera® compared to continuing on Atripla® (EfaRiLipidomics) | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005127-34 | Sponsor Protocol Number: 0518-018 | Start Date*: 2006-03-14 | |||||||||||
Sponsor Name:Merck & Co. Inc. | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Opt... | |||||||||||||
Medical condition: Unspecified human immuno-deficiency virus [HIV] disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002070-35 | Sponsor Protocol Number: MUC_NewEra_3.1 | Start Date*: 2009-05-13 | |||||||||||
Sponsor Name:MUC Research GmbH | |||||||||||||
Full Title: NEW ERA STUDY HIV and Eradication: A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected... | |||||||||||||
Medical condition: Human immuno-deficiency virus [HIV] disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006448-23 | Sponsor Protocol Number: PIVOT | Start Date*: 2008-12-15 | |||||||||||
Sponsor Name:Medical Research Council | |||||||||||||
Full Title: A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infecte... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003163-31 | Sponsor Protocol Number: AI424-328 | Start Date*: 2006-11-28 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjec... | |||||||||||||
Medical condition: HIV infected Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005113-21 | Sponsor Protocol Number: RDEA806-202 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005854-21 | Sponsor Protocol Number: RDEA806-201 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:Ardea Biosciences Inc. | |||||||||||||
Full Title: A multicenter Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept trial to determine the antiviral activity, pharmacokinetics, tolerability and safety of RDEA806 in HIV-1 posit... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003880-79 | Sponsor Protocol Number: EBONY | Start Date*: 2019-03-15 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologica... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013795-44 | Sponsor Protocol Number: NCHECR-ENCORE1 | Start Date*: 2012-06-21 | ||||||||||||||||
Sponsor Name:The Kirby Institute (formerly National Centre in HIV Epidemiology and Clinical Research (NCHECR)), University of New Sou | ||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase in... | ||||||||||||||||||
Medical condition: Human Immunodeficiency Virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003501-10 | Sponsor Protocol Number: 3883 | Start Date*: 2013-04-24 | |||||||||||
Sponsor Name:Vall d'Hebron Institut de Recerca (VHIR) | |||||||||||||
Full Title: Efficacy of dual antiretroviral treatment with maraviroc plus ritonavir-boosted darunavir in early rescue therapy in patients with HIV-1 infection: pilot, multicenter, randomized, controlled and op... | |||||||||||||
Medical condition: Adult patients with HIV-1 infection that present virologic failure to first-line antiretroviral treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004631-37 | Sponsor Protocol Number: TMC114-TiDP29-C230 | Start Date*: 2009-06-25 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004476-12 | Sponsor Protocol Number: NCHECR001 | Start Date*: 2007-07-10 | |||||||||||
Sponsor Name:University of New South Wales | |||||||||||||
Full Title: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. | |||||||||||||
Medical condition: Chronic HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IE (Completed) DE (Ongoing) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001348-39 | Sponsor Protocol Number: SEM-TAR-01-2014 | Start Date*: 2014-12-03 | ||||||||||||||||
Sponsor Name:Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI) | ||||||||||||||||||
Full Title: A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients | ||||||||||||||||||
Medical condition: HIV-1 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001778-21 | Sponsor Protocol Number: A4001028 | Start Date*: 2005-02-02 |
Sponsor Name:PFIZER LTD | ||
Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f... | ||
Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
